Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
Int J Mol Sci ; 22(7)2021 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-33810274

RESUMEN

The carbazole compounds PK9320 (1-(9-ethyl-7-(furan-2-yl)-9H-carbazol-3-yl)-N-methylmethanamine) and PK9323 (1-(9-ethyl-7-(thiazol-4-yl)-9H-carbazol-3-yl)-N-methylmethanamine), second-generation analogues of PK083 (1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine), restore p53 signaling in Y220C p53-mutated cancer cells by binding to a mutation-induced surface crevice and acting as molecular chaperones. In the present paper, these three molecules have been tested for mutant p53-independent genotoxic and epigenomic effects on wild-type p53 MCF-7 breast adenocarcinoma cells, employing a combination of Western blot for phospho-γH2AX histone, Comet assay and methylation-sensitive arbitrarily primed PCR to analyze their intrinsic DNA damage-inducing and DNA methylation-changing abilities. We demonstrate that small modifications in the substitution patterns of carbazoles can have profound effects on their intrinsic genotoxic and epigenetic properties, with PK9320 and PK9323 being eligible candidates as "anticancer compounds" and "anticancer epi-compounds" and PK083 a "damage-corrective" compound on human breast adenocarcinoma cells. Such different properties may be exploited for their use as anticancer agents and chemical probes.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias de la Mama/metabolismo , Carbazoles/farmacología , Mutágenos/farmacología , Antineoplásicos/química , Neoplasias de la Mama/genética , Carbazoles/química , Daño del ADN , Metilación de ADN , Epigénesis Genética/efectos de los fármacos , Femenino , Histonas/metabolismo , Humanos , Células MCF-7 , Mutágenos/química , Transducción de Señal , Proteína p53 Supresora de Tumor/metabolismo
2.
Org Biomol Chem ; 16(2): 336, 2018 01 03.
Artículo en Inglés | MEDLINE | ID: mdl-29256564

RESUMEN

Correction for 'Synthesis of kinase inhibitors containing a pentafluorosulfanyl moiety' by Supojjanee Sansook et al., Org. Biomol. Chem., 2017, 15, 8655-8660.

3.
Org Biomol Chem ; 15(40): 8655-8660, 2017 Oct 18.
Artículo en Inglés | MEDLINE | ID: mdl-28984325

RESUMEN

A series of 3-methylidene-1H-indol-2(3H)-ones substituted with a 5- or 6-pentafluorosulfanyl group has been synthesized by a Knoevenagel condensation reaction of SF5-substituted oxindoles with a range of aldehydes. The resulting products were characterized by X-ray crystallography studies and were tested for biological activity versus a panel of cell lines and protein kinases. Some exhibited single digit nM activity.


Asunto(s)
Fluoruros/farmacología , Indoles/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Quinasas/metabolismo , Compuestos de Azufre/farmacología , Línea Celular , Proliferación Celular/efectos de los fármacos , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Fluoruros/síntesis química , Fluoruros/química , Humanos , Indoles/síntesis química , Indoles/química , Modelos Moleculares , Estructura Molecular , Oxindoles , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/química , Relación Estructura-Actividad , Compuestos de Azufre/síntesis química , Compuestos de Azufre/química
4.
Org Biomol Chem ; 14(35): 8246-52, 2016 Sep 21.
Artículo en Inglés | MEDLINE | ID: mdl-27453149

RESUMEN

Nitration of three regioisomers of bromo-fluorobenzaldehyde proceeds regioselectively, notably with H2SO4/HNO3 at 0 °C. The thereby synthesized tetrasubstituted aromatics, endowed with orthogonal substituents, can be elaborated via Pd-catalysed coupling, reduction and reductive amination reactions. As a test-case, these compounds were converted into EGFR inhibitors related to Gefitinib, whose activity was rationalised by docking studies.


Asunto(s)
Receptores ErbB/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Bibliotecas de Moléculas Pequeñas/química , Aminación , Animales , Células CHO , Catálisis , Cricetulus , Descubrimiento de Drogas/métodos , Receptores ErbB/metabolismo , Gefitinib , Humanos , Simulación del Acoplamiento Molecular , Estructura Molecular , Paladio/química , Inhibidores de Proteínas Quinasas/síntesis química , Quinazolinas/química , Bibliotecas de Moléculas Pequeñas/síntesis química , Estereoisomerismo , Relación Estructura-Actividad
5.
Cell Rep ; 43(5): 114224, 2024 May 28.
Artículo en Inglés | MEDLINE | ID: mdl-38733589

RESUMEN

Metastasis is one of the defining features of pancreatic ductal adenocarcinoma (PDAC) that contributes to poor prognosis. In this study, the palmitoyl transferase ZDHHC20 was identified in an in vivo short hairpin RNA (shRNA) screen as critical for metastatic outgrowth, with no effect on proliferation and migration in vitro or primary PDAC growth in mice. This phenotype is abrogated in immunocompromised animals and animals with depleted natural killer (NK) cells, indicating that ZDHHC20 affects the interaction of tumor cells and the innate immune system. Using a chemical genetics platform for ZDHHC20-specific substrate profiling, a number of substrates of this enzyme were identified. These results describe a role for palmitoylation in enabling distant metastasis that could not have been detected using in vitro screening approaches and identify potential effectors through which ZDHHC20 promotes metastasis of PDAC.


Asunto(s)
Aciltransferasas , Carcinoma Ductal Pancreático , Metástasis de la Neoplasia , Neoplasias Pancreáticas , Animales , Humanos , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/genética , Aciltransferasas/metabolismo , Aciltransferasas/genética , Ratones , Carcinoma Ductal Pancreático/patología , Carcinoma Ductal Pancreático/genética , Línea Celular Tumoral , Proliferación Celular , Movimiento Celular , Células Asesinas Naturales/inmunología , Células Asesinas Naturales/metabolismo , Lipoilación
6.
Nat Biotechnol ; 2024 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-38191663

RESUMEN

The 23 human zinc finger Asp-His-His-Cys motif-containing (ZDHHC) S-acyltransferases catalyze long-chain S-acylation at cysteine residues across an extensive network of hundreds of proteins important for normal physiology or dysregulated in disease. Here we present a technology to directly map the protein substrates of a specific ZDHHC at the whole-proteome level, in intact cells. Structure-guided engineering of paired ZDHHC 'hole' mutants and 'bumped' chemically tagged fatty acid probes enabled probe transfer to specific protein substrates with excellent selectivity over wild-type ZDHHCs. Chemical-genetic systems were exemplified for five human ZDHHCs (3, 7, 11, 15 and 20) and applied to generate de novo ZDHHC substrate profiles, identifying >300 substrates and S-acylation sites for new functionally diverse proteins across multiple cell lines. We expect that this platform will elucidate S-acylation biology for a wide range of models and organisms.

7.
Proc Natl Acad Sci U S A ; 106(33): 14132-7, 2009 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-19666565

RESUMEN

Inappropriate activation of the Hedgehog (Hh) signaling pathway has been implicated in a diverse spectrum of cancers, and its pharmacological blockade has emerged as an anti-tumor strategy. While nearly all known Hh pathway antagonists target the transmembrane protein Smoothened (Smo), small molecules that suppress downstream effectors could more comprehensively remediate Hh pathway-dependent tumors. We report here four Hh pathway antagonists that are epistatic to the nucleocytoplasmic regulator Suppressor of Fused [Su(fu)], including two that can inhibit Hh target gene expression induced by overexpression of the Gli transcription factors. Each inhibitor has a unique mechanism of action, and their phenotypes reveal that Gli processing, Gli activation, and primary cilia formation are pharmacologically targetable. We further establish the ability of certain compounds to block the proliferation of cerebellar granule neuron precursors expressing an oncogenic form of Smo, and we demonstrate that Hh pathway inhibitors can have tissue-specific activities. These antagonists therefore constitute a valuable set of chemical tools for interrogating downstream Hh signaling mechanisms and for developing chemotherapies against Hh pathway-related cancers.


Asunto(s)
Regulación Neoplásica de la Expresión Génica , Proteínas Hedgehog/antagonistas & inhibidores , Proteínas Hedgehog/metabolismo , Neoplasias/metabolismo , Animales , Química Farmacéutica/métodos , Diseño de Fármacos , Epistasis Genética , Fibroblastos/metabolismo , Humanos , Ratones , Modelos Biológicos , Células 3T3 NIH , Neuronas/metabolismo , Fenotipo , Unión Proteica
8.
RSC Chem Biol ; 1(2): 68-78, 2020 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-34458749

RESUMEN

Zymoseptoria tritici is the causative agent of Septoria tritici blotch (STB), which costs billions of dollars annually to major wheat-producing countries in terms of both fungicide use and crop loss. Agricultural pathogenic fungi have acquired resistance to most commercially available fungicide classes, and the rate of discovery and development of new fungicides has stalled, demanding new approaches and insights. Here we investigate a potential mechanism of targeting an important wheat pathogen Z. tritici via inhibition of N-myristoyltransferase (NMT). We characterize Z. tritici NMT biochemically for the first time, profile the in vivo Z. tritici myristoylated proteome and identify and validate the first Z. tritici NMT inhibitors. Proteomic investigation of the downstream effects of NMT inhibition identified an unusual and novel mechanism of defense against chemical toxicity in Z. tritici through the application of comparative bioinformatics to deconvolute function from the previously largely unannotated Z. tritici proteome. Research into novel fungicidal modes-of-action is essential to satisfy an urgent unmet need for novel fungicide targets, and we anticipate that this study will serve as a useful proteomics and bioinformatics resource for researchers studying Z. tritici.

9.
Angew Chem Int Ed Engl ; 48(13): 2321-4, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19222062

RESUMEN

Eradicating hedgehogs: The title molecule has been previously identified as a potent inhibitor of the Hedgehog signaling pathway, which gives embryonic cells information needed to develop properly. This molecule is shown to modulate Hedgehog target gene expression by depolymerizing microtubules, thus revealing dual roles of the cytoskeleton in pathway regulation (see figure).


Asunto(s)
Proteínas Hedgehog/metabolismo , Compuestos Heterocíclicos con 2 Anillos/farmacología , Microtúbulos/metabolismo , Tiazoles/farmacología , Animales , Línea Celular , Regulación del Desarrollo de la Expresión Génica , Proteínas Hedgehog/antagonistas & inhibidores , Compuestos Heterocíclicos con 2 Anillos/química , Ratones , Microtúbulos/efectos de los fármacos , Células 3T3 NIH , Piridinas/química , Transducción de Señal , Tiazoles/química
10.
Chem Sci ; 10(39): 8995-9000, 2019 Oct 21.
Artículo en Inglés | MEDLINE | ID: mdl-31762980

RESUMEN

Posttranslational attachment of lipids to proteins is important for many cellular functions, and the enzymes responsible for these modifications are implicated in many diseases, from cancer to neurodegeneration. Lipid transferases and hydrolases are increasingly tractable therapeutic targets, but present unique challenges for high-throughput biochemical enzyme assays which hinder development of new inhibitors. We present Acylation-coupled Lipophilic Induction of Polarisation (Acyl-cLIP) as the first universally applicable biochemical lipidation assay, exploiting the hydrophobic nature of lipidated peptides to drive a polarised fluorescence readout. Acyl-cLIP allows sensitive, accurate, real-time measurement of S- or N-palmitoylation, N-myristoylation, S-farnesylation or S-geranylgeranylation. Furthermore, it is applicable to transfer and hydrolysis reactions, and we demonstrate its extension to a high-throughput screening format. We anticipate that Acyl-cLIP will greatly expedite future drug discovery efforts against these challenging targets.

11.
Bioorg Med Chem ; 16(2): 762-70, 2008 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-17988877

RESUMEN

Analogs of the TRalpha-specific thyromimetic CO23 were synthesized and analyzed in vitro using competitive binding and transactivation assays. Like CO23, all analogs bind to both thyroid hormone receptor subtypes with about the same affinity; however, modification of CO23 by derivatization of the 3' position of the outer-ring or replacement of the inner-ring iodides with bromides attenuates binding. Despite lacking a preference in binding to TRalpha, all analogs display TRalpha-specificity in transactivation assays using U2OS and HeLa cells. At best, several agonists exhibit an approximately 6-12-fold preference in transactivation when tested with TRalpha in HeLa cells. One analog, CO24, showed in vivo TRalpha-specific action in a tadpole metamorphosis assay.


Asunto(s)
Hidantoínas/síntesis química , Hidantoínas/farmacología , Metamorfosis Biológica/efectos de los fármacos , Receptores alfa de Hormona Tiroidea/química , Receptores alfa de Hormona Tiroidea/metabolismo , Animales , Técnicas Químicas Combinatorias , Ensayos de Selección de Medicamentos Antitumorales , Células HeLa , Humanos , Hidantoínas/química , Larva/efectos de los fármacos , Estructura Molecular , Células Tumorales Cultivadas , Xenopus laevis
12.
ACS Chem Biol ; 13(10): 2956-2965, 2018 10 19.
Artículo en Inglés | MEDLINE | ID: mdl-30239186

RESUMEN

Analogue-sensitive (AS) kinases contain large to small mutations in the gatekeeper position rendering them susceptible to inhibition with bulky analogues of pyrazolopyrimidine-based Src kinase inhibitors (e.g., PP1). This "bump-hole" method has been utilized for at least 85 of ∼520 kinases, but many kinases are intolerant to this approach. To expand the scope of AS kinase technology, we designed type II kinase inhibitors, ASDO2/6 (analogue-sensitive "DFG-out" kinase inhibitors 2 and 6), that target the "DFG-out" conformation of Cys-gatekeeper kinases with submicromolar potency. We validated this system in vitro against Greatwall kinase (GWL), Aurora-A kinase, and cyclin-dependent kinase-1 and in cells using M110C-GWL-expressing mouse embryonic fibroblasts. These Cys-gatekeeper kinases were sensitive to ASDO2/6 inhibition but not AS kinase inhibitor 3MB-PP1 and vice versa. These compounds, with AS kinase inhibitors, have the potential to inhibit multiple AS kinases independently with applications in systems level and translational kinase research as well as the rational design of type II kinase inhibitors targeting endogenous kinases.


Asunto(s)
Inhibidores de Proteínas Quinasas/metabolismo , Proteínas Quinasas/metabolismo , Pirazoles/química , Pirimidinas/química , Animales , Sitios de Unión , Células HEK293 , Humanos , Ratones , Mutación , Unión Proteica , Conformación Proteica , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/química , Proteínas Quinasas/química , Proteínas Quinasas/genética , Purinas/química , Pirazoles/síntesis química , Pirazoles/farmacología , Pirimidinas/síntesis química , Pirimidinas/farmacología , Xenopus
13.
Sci STKE ; 2006(341): pl3, 2006 Jun 27.
Artículo en Inglés | MEDLINE | ID: mdl-16804159

RESUMEN

To provide alternative methods for regulation of gene transcription initiated by the binding of thyroid hormone (T3) to the thyroid receptor (TR), we have developed a high-throughput method for discovering inhibitors of the interaction of TR with its transcriptional coactivators. The screening method is based on fluorescence polarization (FP), one of the most sensitive and robust high-throughput methods for the study of protein-protein interactions. A fluorescently labeled coactivator is excited by polarized light. The emitted polarized light is a function of the molecular properties of the labeled coactivator, especially Brownian molecular rotation, which is very sensitive to changes in the molecular mass of the labeled complex. Dissociation of hormone receptor from fluorescently labeled coactivator peptide in the presence of small molecules can be detected by this competition method, and the assay can be performed in a high-throughput screening format. Hit compounds identified by this method are evaluated by several secondary assay methods, including a dose-response analysis, a semiquantitative glutathione-S-transferase assay, and a hormone displacement assay. Subsequent in vitro transcription assays can detect inhibition of thyroid signaling at low micromolar concentrations of small molecules in the presence of T3.


Asunto(s)
Acetiltransferasas/antagonistas & inhibidores , Evaluación Preclínica de Medicamentos/métodos , Polarización de Fluorescencia/métodos , Receptores de Hormona Tiroidea/efectos de los fármacos , Transactivadores/antagonistas & inhibidores , Acetiltransferasas/metabolismo , Unión Competitiva , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Glutatión Transferasa/análisis , Histona Acetiltransferasas , Humanos , Indicadores y Reactivos , Peso Molecular , Coactivador 3 de Receptor Nuclear , Concentración Osmolar , Fotoquímica , Unión Proteica , Receptores de Hormona Tiroidea/metabolismo , Rotación , Sensibilidad y Especificidad , Transactivadores/metabolismo
14.
Oncotarget ; 7(44): 71182-71197, 2016 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-27563826

RESUMEN

MASTL (microtubule-associated serine/threonine kinase-like), more commonly known as Greatwall (GWL), has been proposed as a novel cancer therapy target. GWL plays a crucial role in mitotic progression, via its known substrates ENSA/ARPP19, which when phosphorylated inactivate PP2A/B55 phosphatase. When over-expressed in breast cancer, GWL induces oncogenic properties such as transformation and invasiveness. Conversely, down-regulation of GWL selectively sensitises tumour cells to chemotherapy. Here we describe the first structure of the GWL minimal kinase domain and development of a small-molecule inhibitor GKI-1 (Greatwall Kinase Inhibitor-1). In vitro, GKI-1 inhibits full-length human GWL, and shows cellular efficacy. Treatment of HeLa cells with GKI-1 reduces ENSA/ARPP19 phosphorylation levels, such that they are comparable to those obtained by siRNA depletion of GWL; resulting in a decrease in mitotic events, mitotic arrest/cell death and cytokinesis failure. Furthermore, GKI-1 will be a useful starting point for the development of more potent and selective GWL inhibitors.


Asunto(s)
Proteínas Asociadas a Microtúbulos/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/síntesis química , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Cristalización , Células HeLa , Humanos , Proteínas Asociadas a Microtúbulos/química , Fosforilación , Dominios Proteicos , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Serina-Treonina Quinasas/química , Relación Estructura-Actividad
15.
Nat Med ; 17(11): 1504-8, 2011 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-21983857

RESUMEN

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer for which there is no effective treatment. Using a mouse model in which deletion of Rb1 and Trp53 in the lung epithelium of adult mice induces SCLC, we found that the Hedgehog signaling pathway is activated in SCLC cells independently of the lung microenvironment. Constitutive activation of the Hedgehog signaling molecule Smoothened (Smo) promoted the clonogenicity of human SCLC in vitro and the initiation and progression of mouse SCLC in vivo. Reciprocally, deletion of Smo in Rb1 and Trp53-mutant lung epithelial cells strongly suppressed SCLC initiation and progression in mice. Furthermore, pharmacological blockade of Hedgehog signaling inhibited the growth of mouse and human SCLC, most notably following chemotherapy. These findings show a crucial cell-intrinsic role for Hedgehog signaling in the development and maintenance of SCLC and identify Hedgehog pathway inhibition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in individuals with SCLC.


Asunto(s)
Proteínas Hedgehog/metabolismo , Neoplasias Pulmonares/metabolismo , Transducción de Señal/fisiología , Carcinoma Pulmonar de Células Pequeñas/metabolismo , Animales , Modelos Animales de Enfermedad , Resistencia a Antineoplásicos , Células Epiteliales/citología , Células Epiteliales/fisiología , Proteínas Hedgehog/genética , Humanos , Pulmón/citología , Pulmón/metabolismo , Pulmón/patología , Neoplasias Pulmonares/patología , Ratones , Ratones Noqueados , Ratones Desnudos , Trasplante de Neoplasias , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Proteína de Retinoblastoma/genética , Proteína de Retinoblastoma/metabolismo , Carcinoma Pulmonar de Células Pequeñas/patología , Trasplante Heterólogo , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo
16.
ACS Chem Biol ; 1(9): 585-93, 2006 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-17168554

RESUMEN

Thyroid hormone is a classical endocrine signaling molecule that regulates a diverse array of physiological processes ranging from energy metabolism to cardiac performance. The active form of thyroid hormone, 3,5,3'-triiodo- l -thyronine or T 3 , exerts many of its actions through its receptor, the thyroid hormone receptor (TR), of which there are two subtypes for two isoforms: TRalpha 1 , TRalpha 2 , TRbeta 1 , and TRbeta 2 . Although TR isoforms, with the exception of TRbeta 2 , are expressed in all tissues, they display different patterns of expression in different tissues, giving rise to tissue-specific isoform actions. Currently, several TRbeta-selective agonists have been developed; however, TRalpha-selective agonists have remained elusive. Herein, we report the synthesis and biological evaluation of CO23, the first potent thyromimetic with TRalpha-specific effects in vitro and in vivo .


Asunto(s)
Hidantoínas/farmacología , Receptores alfa de Hormona Tiroidea/agonistas , Hormonas Tiroideas/química , Animales , Línea Celular Tumoral , Diseño de Fármacos , Regulación de la Expresión Génica , Humanos , Cinética , Modelos Químicos , Unión Proteica , Isoformas de Proteínas , Transducción de Señal , Receptores alfa de Hormona Tiroidea/metabolismo , Hormonas Tiroideas/metabolismo , Distribución Tisular , Activación Transcripcional , Xenopus
17.
J Am Chem Soc ; 124(46): 13795-805, 2002 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-12431109

RESUMEN

The nuclear and steroid hormone receptors function as ligand-dependent transcriptional regulators of diverse sets of genes associated with development and homeostasis. Mutations to the vitamin D receptor (VDR), a member of the nuclear and steroid hormone receptor family, have been linked to human vitamin D-resistant rickets (hVDRR) and result in high serum 1,25(OH)(2)D(3) concentrations and severe bone underdevelopment. Several hVDRR-associated mutants have been localized to the ligand binding domain of VDR and cause a reduction in or loss of ligand binding and ligand-dependent transactivation function. The missense mutation Arg274 --> Leu causes a >1000-fold reduction in 1,25(OH)(2)D(3) responsiveness and is, therefore, no longer regulated by physiological concentrations of the hormone. In this study, computer-aided molecular design was used to generate a focused library of nonsteroidal analogues of the VDR agonist LG190155 that were uniquely designed to complement the Arg274 --> Leu associated with hVDRR. Half of the designed analogues exhibit substantial activity in the hVDRR-associated mutant, whereas none of the structurally similar control compounds exhibited significant activity. The seven most active designed analogues were more than 16 to 526 times more potent than 1,25(OH)(2)D(3) in the mutant receptor (EC(50) = 3.3-121 nM). Significantly, the analogues are selective for the nuclear VDR and did not stimulate cellular calcium influx, which is associated with activation of the membrane-associated vitamin D receptor.


Asunto(s)
Compuestos de Bifenilo/química , Calcitriol/química , Cetonas/química , Receptores de Calcitriol/agonistas , Raquitismo/genética , Compuestos de Bifenilo/farmacología , Calcitriol/farmacología , Calcio/metabolismo , Membrana Celular/metabolismo , Células Cultivadas , Diseño de Fármacos , Humanos , Cetonas/farmacología , Modelos Moleculares , Método de Montecarlo , Mutación Missense , Receptores de Calcitriol/química , Receptores de Calcitriol/genética , Relación Estructura-Actividad , Activación Transcripcional/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA